Lipid-lowering medications

Wittemans LBL, Lotta LA, Langenberg C. Curr Diab Rep 2018; 18: 40. doi: 10.1007/s11892-018-1009-1

Owusu Adjah ES et al. Cardiovasc Diabetol 2018; 17: 70. doi: 10.1186/s12933-018-0712-1

Ginsberg HN et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0439-8

Prospective Studies Collaboration and Asia Pacific Cohort Studies Collaboration. Lancet Diabetes Endocrinol 2018; Advance online publication. doi: 10.1016/S2213-8587(18)30079-2

Gant CM et al. Nutr Diabetes 2018; 8: 24. doi: 10.1038/s41387-018-0028-y

Itho H et al. Diabetes Care 2018; Advance online publication. doi: 10.2337/dc17-2224

The anti-cholesterol medication fenofibrate significantly reduces uric acid levels and more than halves the risk for gout in patients with type 2 diabetes, shows an analysis of the FIELD cohort.

Saxon DR, Rasouli N, Eckel RH. Drugs 2018; 78: 203–214. doi: 10.1007/s40265-017-0857-3

Scicali R et al. Acta Diabetol 2017; 55: 209–218. doi: 10.1007/s00592-017-1089-4

Results of AdDIT show that treatment with an ACE inhibitor, a statin, or both does not protect against the increased albumin excretion that frequently occurs in patients with type 1 diabetes during adolescence.

A prespecified analysis of the FOURIER trial shows that the PCSK9 inhibitor evolocumab is as beneficial in patients with diabetes as in those without.

The effect of the PCSK9 inhibitor alirocumab on dyslipidemia in patients with type 1 diabetes is consistent with that seen in the type 2 population, the ODYSSEY team has revealed.

An analysis in JAMA shows that the price of PCSK9 inhibitors, recently shown to be effective against diabetic dyslipidemia, will need to fall by nearly three-quarters before they can be considered cost-effective even in high-risk patients with established cardiovascular disease.

Laakso M, Kuusisto J. Curr Diab Rep 2017; 17: 10. doi: 10.1007/s11892-017-0837-8

Data from the ODYSSEY series of trials, presented at the American Diabetes Association scientific sessions, show that the PCSK9 inhibitor alirocumab reduces atherogenic dyslipidemia in patients with diabetes.

Researchers find that the increased risk for type 2 diabetes among patients taking statins is limited to the least fit individuals.

​​​​​​​Nat Rev Endocrinol 2017; 13: 36–49. doi: 10.1038/nrendo.2016.135

Khavandi M et al. Curr Cardiol Rep 2017; 19: 7. doi: 10.1007/s11886-017-0818-1